Close

Jump to:

  • Navigation
  • Content
  • Footer
Felcana hero image

Felcana

Follow

Felcana is the Digital Pet Health Platform that provides digital health services to pet owners and vets.

416%
 - 
Funded 14 Jul 2019
£80,009 target
£343,926 from 380 investors
More
Less

Business overview

Location London, United Kingdom
Social media
Website felcana.com/
Sectors Healthcare Digital Mixed B2B/B2C
Company number 09521139
Incorporation date 1 Apr 2015
More
Less

Investment summary

Type Equity
Valuation (pre-money) £3.8M
Equity offered 8.14%
Tax relief

EIS

  • Idea
  • Team
  • Updates
  • Investors 380
  • Discussion
  • Documents

Idea

Introduction

Digital technology is disrupting pet care in line with other industries. Felcana is building the future of intelligent pet care. We help owners look after their pet’s health and provide vets with the data they need. Our products and services connect owners with their pets through state-of-the-art wearables and AI-based telehealth. With Felcana, users can gain on-demand online veterinary advice and critical insights into their pet’s health and well-being. We aim to be the go-to source for credible veterinary advice.

Thanks to an overfunded Seedrs campaign in 2018, we have delivered on our objectives, launched Felcana Go and are now entering our next phase - COMMERCIALISATION.

Backed by venture capital investors, Innovate UK and leading vets. Our world-class team of veterinarians and engineers have designed Felcana to be the best for owners, pets and their vets.

Felcana’s vet founders are building a leading pet care company that uses digital technology to pioneer a new generation of care.

Intended impact

Euromonitor estimates the global population of pet dogs and cats at 630M+ supporting a market worth over $130 billion in 2016. The pet care market is predicted to grow at 5% CAGR until 2025, driven by willingness to spend on pets and growing pet ownership.

Connecting information between pets, owners and vets enables a step-change in how we predict, simplify, and treat pet health problems. Felcana’s products and services provide convenience and value to:

• PET OWNERS: 24-hour monitoring, convenient telemedicine consultations and reduced treatment costs through earlier detection of health problems.
• VETS: data to support diagnosis and monitor treatment. Telemedicine enables vets to work more efficiently by prioritising their caseload while also providing a convenient emergency out-of-hours service.
• PET CARE COMPANIES: direct marketing through a deeper understanding of their client base and differentiation from competitors.
• PET INSURERS: help policy pricing and monitor claims.

Substantial accomplishments to date

SALES TRACTION & DISTRIBUTION.
Currently, we have users in 35 countries. Our userbase is growing quickly, this month sales on felcana.com grew 139%. New users will be won through the expansion of our Strategic Partnerships and existing B2C network.

Our Strategic Partnership with Simplyhealth is going from strength-to-strength; through this Partnership we plan to have a national presence across veterinary clinics by the end of 2019. Further partnerships with leading pet insurers are expected to launch later in 2019. Advanced discussions are ongoing with a large group of UK veterinary clinics and multiple international distributors.

PRODUCT INNOVATION & IP.
Over the past two years, we have been busy perfecting our first product, Felcana Go, which launched to rave reviews.

To support our products and services, Felcana’s sophisticated cloud-based software analytics platform is up and running. Our supply chain is built and tooling is complete. Two patents are filed: one for our overall system and beacon technology; and one for a range-extending antenna technology.

In 2018, we launched a four-year research collaboration with the Royal Veterinary College, ranked as the world’s number one veterinary school, who support Felcana with data collection and analysis.

TEAM.
Built an expert team with broad capabilities, ranging from product design to public relations. Our team have previously worked at companies such as Bain & Company, Accenture and Dyson.

Monetisation strategy

We are commercialising our products and services through B2B and B2C channels:
• B2B sales through pet health plan providers, pet insurers, veterinary clinics and pharmaceutical companies.
• B2C channels such as our own website and 3rd party retailers.

Currently, we make money selling Felcana Go. We will be introducing a subscription model later in 2019 to provide a recurring revenue stream. Other future high-margin revenue streams include direct marketing to our user-base, commissions and licencing of our IP.

Our launch product, Felcana Go, has a RRP of £69.99. Our expertise in procurement and supply chain enables us to maintain a gross margin over 50% at low production volumes. Our on-demand veterinary advice services, due to launch later in 2019, will be provided via a freemium subscription model.

We plan to expand internationally using distribution and licence agreements. We are in discussions with large distributors in multiple countries.

Use of proceeds

We are executing this funding round to continue scaling up business operations while also investing in new product development. Use of proceeds is detailed below.

MARKETING AND SALES:
• Grow customer reach and brand awareness through increased marketing expenditure.
• Launch additional pilots with pet insurance companies and other industry players.
• Expand our consumer reach through additional retailer presence in select national retailers and internal direct to consumer sales campaigns through Felcana.com.
• Scale our commercial and marketing team.
• Attend trade events such as the London Vet Show in November.

NEW PRODUCT DEVELOPMENT:
• Launch our new on-demand veterinary service in 2019.
• Expand the health insights our data science team can generate.
• Grow our research collaborations with the Royal Veterinary College.
• Build up larger production runs to support product demand and increase efficiencies of scale.

This will pave the way for Felcana’s continued commercialisation.

Open an account to get access to the team members of Felcana

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Share on:

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This campaign for Felcana has been approved by Seedrs Limited (trading as Republic Europe) ("Republic Europe", "us" or "we"), as of 17 May 2019 as a financial promotion. Republic Europe is authorised and regulated by the Financial Conduct Authority with firm reference number 550317. In approving this campaign, Republic Europe has concluded that the information, taken as a whole, is "fair, clear and not misleading." This means that for factual statements we have reviewed evidence of their accuracy, and that for aspirational statements we believe they are phrased appropriately in light of their speculative nature. You should note that in the case of factual statements, the evidence we review is provided by the business, and we do not audit it, which means that we may not be able to identify forged or altered evidence. You should further note that in the case of aspirational statements, the nature of the type of businesses presented on the Republic Europe platform is such that they are likely to have high ambitions, and we may approve statements that convey those ambitions even where we do not believe, or we do not have a view on whether it is likely, that they will be fully realised. The pre-money valuation and investment sought in the campaign are those set by the business: they are not reviewed or established by us, and the valuation is not an independent view of what the business is worth. Given the nature and type of businesses presented on the Republic Europe platform, it is possible that the business has very little cash remaining prior to receiving this investment, and the investment sought may be necessary for the business's on-going existence.

Republic Europe does not make investment recommendations to you. No communications from Republic Europe, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Republic Europe does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Republic Europe, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £3,763,852

This is the fully-diluted pre-money valuation of the business (i.e. before the new investment comes in and including issued options and other equity interests). In contrast, the post-money valuation is based on inclusion of the new investment in the value.

It is calculated as the pre-money valuation plus the amount of new investment. e.g. If Company A is ascribed a pre-money valuation of £1,200,000 by prospective investors investing £300,000, its post-money valuation is £1,500,000.

The investee business is responsible for setting its own valuation, it has not been prescribed by Seedrs.

Pitch type

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Seedrs

Equity Offered

The equity offered is the percentage of the company’s shares being issued in return for the amount of investment raised.

When the amount raised is less than 100%, the equity offered is based on the target raise. Once the company has raised over 100% it is based on the total raised.

In some scenarios, entrepreneurs may accept additional direct investment after closing their Seedrs campaign. Provided this is within 6 months of the closing and on the same terms, we do not typically offer pre-emption rights on that extra investment (where you have the opportunity to invest again to maintain your percentage shareholding).

Learn more about investing and pre-emption rights.

Warning

You are following a link outside of europe.republic.com.

None of the information in constitutes part of the campaign and it has not been approved or reviewed by Seedrs.

ContinueCancel